ProCE Banner Activity

DESTINY-PanTumor01: Phase II Study of Trastuzumab Deruxtecan in Patients With HER2-Activating Mutations in Solid Tumors

Conference Coverage
Slideset

In the DESTINY-PanTumor01 phase II trial, efficacy and safety of T-DXd in patients with solid tumors harboring a prespecified HER2 activating mutation was promising and warrants further study.

Released: November 01, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc